How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comA Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer
Description:
Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.
Sponsor:
Philogen S.p.A.
Phase:
Phase 1
Contacts:
Jacqueline Mock, PhDregulatory@philogen.com
+41 43 544 88 02
Federica Bastioli (Pharmaceutical Chemist)regulatory@philogen.com
+39 057717816
Government Study Link:
NCT06840548 - Click here to see study onClinicalTrials.gov
68Ga-OncoCAIX
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- CAIX
Share your feedback
Help us improve your experience